Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus-Eluting Stents or Bypass Surgery for Multivessel Disease in Diabetics: The BEST Extended Follow-Up Study.
Kim H, Kang DY, Ahn JM, Lee J, Choi Y, Hur SH, Park HJ, Tresukosol D, Kang WC, Kwon HM, Rha SW, Lim DS, Jeong MH, Lee BK, Huang H, Lim YH, Bae JH, Kim BO, Ong TK, Ahn SG, Chung CH, Park DW, Park SJ; BEST Extended Follow-Up Study Investigators. Kim H, et al. Among authors: park sj, park dw, park hj. JACC Cardiovasc Interv. 2023 Oct 9;16(19):2412-2422. doi: 10.1016/j.jcin.2023.07.028. JACC Cardiovasc Interv. 2023. PMID: 37821187 Free article. Clinical Trial.
Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents.
Park HJ, Seo SM, Shin WS, Kim HY, Choi YS, Koh YS, Youn SG, Park MW, Chang K, Kim PJ, Jung HO, Baek SH, Chung WS, Seung KB, Yoo KD. Park HJ, et al. Among authors: park mw. Coron Artery Dis. 2011 Jan;22(1):12-7. doi: 10.1097/mca.0b013e328340b210. Coron Artery Dis. 2011. PMID: 21197704 Clinical Trial.
Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CAtholic Total Occlusion Study (CATOS) trial.
Park HJ, Kim HY, Lee JM, Choi YS, Park CS, Kim DB, Her SH, Koh YS, Park MW, Kwon BJ, Kim PJ, Chang K, Chung WS, Seung KB. Park HJ, et al. Among authors: park cs, park mw. Circ J. 2012;76(4):868-75. doi: 10.1253/circj.cj-11-1021. Epub 2012 Jan 25. Circ J. 2012. PMID: 22277317 Free article. Clinical Trial.
Long-term outcomes of percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main coronary bifurcation disease in the drug-eluting stent era.
Chang K, Koh YS, Jeong SH, Lee JM, Her SH, Park HJ, Kim PJ, Kim YH, Chung WS, Yim HW, Park SJ, Seung KB. Chang K, et al. Among authors: park sj, park hj. Heart. 2012 May;98(10):799-805. doi: 10.1136/heartjnl-2011-300753. Epub 2012 Mar 15. Heart. 2012. PMID: 22422589 Clinical Trial.
Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation.
Choi IJ, Koh YS, Lim S, Kim JJ, Chang M, Kang M, Hwang BH, Kim CJ, Kim TH, Seo SM, Shin DI, Park MW, Choi YS, Park HJ, Her SH, Kim DB, Kim PJ, Lee JM, Park CS, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, Seung KB. Choi IJ, et al. Among authors: park cs, park mw, park hj. Am J Cardiol. 2014 Feb 1;113(3):457-64. doi: 10.1016/j.amjcard.2013.10.029. Epub 2013 Nov 9. Am J Cardiol. 2014. PMID: 24332246
Prognostic importance of mitral regurgitation complicated by acute myocardial infarction during a 5-year follow-up period in the drug-eluting stent era.
Kim TH, Lee KY, Choi Y, Park HW, Lee YS, Koh YS, Park HJ, Kim PJ, Chang K, Chung WS, Kim DB, Her SH, Park CS, Lee JM, Kim HY, Yoo KD, Jeon DS, Ahn Y, Jeong MH, Seung KB. Kim TH, et al. Among authors: park cs, park hw, park hj. Coron Artery Dis. 2016 Mar;27(2):109-15. doi: 10.1097/MCA.0000000000000324. Coron Artery Dis. 2016. PMID: 26626143
6,314 results